State of the Art Food Immunotherapy

Price: FREE for members, $25 non-members

Several new therapies including OIT, EPIT, SLIT, and biologics (monoclonal antibodies) are being evaluated in large scale trials. Allergists need to have the most up to date knowledge of these emerging therapies to be able to educate their patients with food allergies and choose an appropriate therapy for each individual patient.

To review the session without credit, access the video at this link.

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring activity for a maximum of 1.00 AMA PRA Category I Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity was supported by a grant from GENENTECH.

Target Audience

Allergists, allied health and other allergy practitioners.

Learning Objectives

  • Highlight SLIT for foods and where the therapy is headed
  • Discuss the long-term outcomes in OIT
  • Describe the use of biologics and other novel forms of food immunotherapy
Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
Course expires: 

Edwin H. Kim, MD, MS is a pediatric allergist and immunologist whose research focuses on development of novel therapeutics for food allergy. He is currently chief of the UNC division of pediatric allergy and immunology and director of the UNC Food Allergy Initiative (UNC FAI) research group.

Katherine Anagnostou, MD, PhD is a Professor in Pediatrics (Allergy) with expertise in food allergy. Research interests: food immunotherapy, infant anaphylaxis, microbiome, food allergy prevention and quality of life in food allergic individuals.

David Fleischer, MD is a Professor of Pediatrics with a research focus on food allergy, in particular peanut and tree nut allergies. He is interested in why certain patients with food allergies outgrow them more readily and sooner than others. He is also an investigator in treatments for food allergy, including oral, sublingual, and epicutaneous immunotherapies. 

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance


Please login or create an account to take this course.